<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000641978"><TermName>multitargeted receptor tyrosine kinase inhibitor ABT-869</TermName><TermPronunciation>(MUL-tee-TAR-geh-ted reh-SEP-ter TY-ruh-seen KY-nays in-HIH-bih-ter …)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of cancer. Multitargeted receptor tyrosine kinase inhibitor ABT-869 blocks the action of several growth factors. It may also block the growth of new blood vessels that tumors need to grow and may cause cancer cells to die. It is a type of receptor tyrosine kinase inhibitor and a type of angiogensis inhibitor. Also called ABT-869.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722912" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;multitargeted receptor tyrosine kinase inhibitor ABT-869&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722911" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inhibidor del receptor de la tirosina cinasa multidirigido ABT-869&quot;" language="es" id="_4"/><SpanishTermName>inhibidor del receptor de la tirosina cinasa multidirigido ABT-869</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer. El inhibidor del receptor de la tirosina cinasa multidirigido ABT-869 impide la acción de varios factores de crecimiento. También podría impedir la formación de  nuevos vasos sanguíneos que los tumores necesitan para crecer y podría destruir células cancerosas. Es un tipo de inhibidor del receptor de la tirosina cinasa y un tipo de inhibidor de la angiogénesis. También se llama ABT-869.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-07-21</DateFirstPublished></GlossaryTerm>
